In a body blow to attempts to develop a vaccine against the dreaded AIDS, multinational giant, the Merck, halted trials on its experimental drugs when some volunteers became infected with HIV.
The drug makers said Friday that 24 of 741 volunteers who got the vaccine in one segment of the trial later become infected with HIV, which causes AIDS.
In a comparison group of volunteers who got dummy shots, 21 of 762 participants also became infected with HIV.
"It's very disappointing news," said Keith Gottesdiener, head of Merck's clinical infectious disease and vaccine research group. "A major effort to develop a vaccine for HIV really did not deliver on the promise."
The study volunteers were all free of HIV at the start of the experiment. But they were at high risk for getting HIV: most were homosexual men or female sex workers. They were all repeatedly counselled about how to reduce their risk of HIV infections, including use of condoms, according to Merck.
In a statement, the US National Institute of Health (NIH), which partly funded the study, said a data safety monitoring board, reviewing interim results, found the vaccine could not be shown to prevent HIV infection or limit severity of the disease "in those who become infected with HIV as a result of their own behaviours that exposed them to the virus."
The Merck vaccine was the first major test of a new strategy to prevent HIV infection.